An experienced company director and business executive, having served as CEO and director of ASX-listed Babcock & Brown Communities, Primelife and Regeneus, John is a former corporate and executive partner of the law firm Allens where he specialized in M&A, fundraising and corporate advisory. He is a Non-Executive Director of Australian national law firm, Sparke Helmore; biotech company, Biopoint; and US internet services and infrastructure company, Lokket.  John is a member of the Australian Institute of Company Directors, Chair of AIM’s ARC (Audit and Risk Committee), and a member of AIM’s RNC (Remuneration and Nomination Committee).

With over 35 years in the pharmaceutical and bioscience industries, Lusia Guthrie is a technology developer, medtech entrepreneur, company founder, board chair and non-executive director. She started her career as a Medical Laboratory Scientist before joining the Manufacturing Division of FH Faulding & Co (now Mayne Pharma). Lusia then went on to co-found medtech innovation company, LBT Innovations Limited (ASX: LBT), where she was CEO and MD until 2016.  Lusia currently serves as: Chair, Neo-Bionica; Chair, Australian Lung Health Initiative (ALHI), a wholly owned subsidiary of 4D Medical Limited; and Independent Director, WearOptimo. Lusia is also a Member of several industry advisory committees: AMCC (Australian Medtech Manufacturing Centre, DJPR Victorian Government); AIML (Australian Institute for Machine Learning, University of Adelaide); and ARMI (Australian Regenerative Medicine Institute, Monash University).

Michael Israels is the Chief Financial Officer of the Centre for Commercialization of Regenerative Medicine (CCRM), its for-profit venture arm, CCRM Enterprises Inc., holding company, CCRM Enterprises Holdings Ltd and OmniaBio Inc. Prior to joining CCRM, Michael was a Management Consultant advising asset management firms including institutional investors, pension funds, and retail investment firms, and Professional Accountant at Ernst & Young LLP in Canada, U.K. and Barbados;  President of BEST Funds, a Toronto-based venture capital firm raising funds from retail investors, investing in early-stage companies, and reporting to securities regulators; and CEO of Convexus Managed Services Inc., a start-up investment fund administration company for retail investment funds. Michael is a Chartered Professional Accountant (CPA) and Chartered Accountant (CA, Ontario), a Chartered Business Valuator (CBV), and a graduate of the Ivey Business School at Western University.

Dr Jeannie Joughin is an experienced biopharmaceutical and medical device leader with 20+ years’ experience locally and internationally. This experience has come from working in and with companies in Australia and the USA including Bristol-Myers Squibb, Mayne Pharma, CSL and CSL Behring, Enable Injections Inc. and many private/public start-up companies.  Jeannie serves on the Board for OneVentures Healthcare portfolio companies and is Chair of BiVACOR.  Dr Joughin holds a PhD and a Bachelor of Science (Hons) in Immunology from Monash University in Melbourne and a Diploma of Marketing from the Melbourne Business School.

Dr Michael May is President and CEO of CCRM, a Canadian public-private consortium that develops technologies, launches new companies and catalyses investment in regenerative medicine, including cell and gene therapy. Before CCRM, Michael was the President, and co-founder, of Rimon Therapeutics Ltd., a Toronto-based tissue engineering company developing novel medical polymers that possess drug-like activity. In addition, Michael sits on several boards and advisory committees, including the ARM Foundation for Cell & Gene Medicine; AgeX Corporation; panCELLa Inc.; CCRM Enterprises; the International Advisory Board of the Swedish Centre for Advanced Medical Products (CAMP); the Poietis SAB; the Entrepreneurship Leadership Council at the University of Toronto; the Cell and Gene Therapy Insights Editorial Advisory Board; the Commercialization Committee of the International Society for Cell and Gene Therapy and he is the Chairman of ExCellThera Ltd.

Silvio Tiziani is Chief Executive Officer of CCRM Australia and the Director, External Strategy and Engagement of the Australian Regenerative Medicine Institute (ARMI). Silvio has extensive experience in private and public organizations, focusing on laboratory-based organizations in the educational, health and hospital systems. A graduate of the Australian Institute of Company Directors (GAICD), Silvio has a scientific background and qualifications with extensive experience in financial analysis and budget management, business development and strategic planning.